Ultralife

ULBI

Market cap $94.1M

Discover why Zacks rates Ultralife as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore ULBI's struggles with execution risks, margin pressure and commercialization delays that could delay its earnings recovery.

Ultralife NASDAQ: ULBI reported a first-quarter loss for fiscal 2026 as lower sales, production disruptions and higher one-time costs weighed on results, even as management pointed to a record backlog and new product activity as signs of future growth.

Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript

NEWARK, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2026 as follows:

NEWARK, N.Y., May 01, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its first quarter results for the period ended March 31, 2026 before the market opens on Friday, May 8, 2026.

Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript

NEWARK, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the fourth quarter and full year ended December 31, 2025 as follows:

NEWARK, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its fourth quarter results for the period ending December 31, 2025 before the market opens on Tuesday, March 10, 2026.

Ultralife Corporation ( ULBI ) Q3 2025 Earnings Call November 18, 2025 8:30 AM EST Company Participants Michael Manna - President, CEO & Director Philip A. Fain - CFO, Treasurer & Corporate Secretary Conference Call Participants Jody Burfening - Lippert/Heilshorn & Associates, Inc. Presentation Operator Good day, and thank you for standing by.

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: